Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
Hanx Biopharmaceuticals (Wuhan) Co OCF Yield % Explanation
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Hanx Biopharmaceuticals (Wuhan) Co OCF Yield % Related Terms
Hanx Biopharmaceuticals (Wuhan) Co OCF Yield % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hanx Biopharmaceuticals (Wuhan) Co OCF Yield % Chart
Hanx Biopharmaceuticals (Wuhan) Co Annual Data
Trend
Dec23
Dec24
Dec25
OCF Yield %
0.00
0.00
-5.22
Hanx Biopharmaceuticals (Wuhan) Co Semi-Annual Data
Dec23
Dec24
Dec25
OCF Yield %
0.00
0.00
-5.22
HKSE:03378 vs VRTX, REGN, RVMD: OCF Yield % Comparison
For the Biotechnology subindustry, Hanx Biopharmaceuticals (Wuhan) Co's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hanx Biopharmaceuticals (Wuhan) Co OCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Hanx Biopharmaceuticals (Wuhan) Co's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Hanx Biopharmaceuticals (Wuhan) Co's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hanx Biopharmaceuticals (Wuhan) Co (HKSE:03378) has a OCF Yield % of -3.06 as of Jul. 30, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Hanx Biopharmaceuticals (Wuhan) Co and its competitors. According to the industry distribution chart, Hanx Biopharmaceuticals (Wuhan) Co ranks #484 out of 1410 companies in the Biotechnology industry, placing it in the top 34.3%.
Is Hanx Biopharmaceuticals (Wuhan) Co's OCF Yield % too high?
Hanx Biopharmaceuticals (Wuhan) Co's current OCF Yield % is -3.06. Based on the distribution chart, Hanx Biopharmaceuticals (Wuhan) Co ranks #484 out of 1410 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Hanx Biopharmaceuticals (Wuhan) Co has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Hanx Biopharmaceuticals (Wuhan) Co's OCF Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Hanx Biopharmaceuticals (Wuhan) Co ranks #484 out of 1410 companies for OCF Yield %. This puts Hanx Biopharmaceuticals (Wuhan) Co in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Biotechnology company?
A good OCF Yield % depends on the Biotechnology industry context. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Hanx Biopharmaceuticals (Wuhan) Co and its competitors. Hanx Biopharmaceuticals (Wuhan) Co's current OCF Yield % is -3.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hanx Biopharmaceuticals (Wuhan) Co stock overvalued right now?
Hanx Biopharmaceuticals (Wuhan) Co (HKSE:03378) has a current OCF Yield % of -3.06. The current OCF Yield % is -3.06. Hanx Biopharmaceuticals (Wuhan) Co's overall GF Score™ is 11/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Hanx Biopharmaceuticals (Wuhan) Co (HKSE:03378), the current OCF Yield % is -3.06 as of Jul. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Hanx Biopharmaceuticals (Wuhan) Co Business Description
Hanx Biopharmaceuticals (Wuhan) Co Ltd is a biotech company with in-house capabilities in structural biology, translational medicine, and clinical development, focused on developing immunotherapeutic products. Its product pipeline comprises one Core Product and nine other pipeline candidates: three clinical-stage drug candidates focused on oncology, including its Core Product HX009 and Key Products HX301 and HX044; and seven preclinical-stage drug candidates, including an antibody drug conjugate, a bispecific antibody, and a monoclonal antibody for both autoimmune and oncology markets.
11GF Score
Get the complete analysis for HKSE:03378
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:03378 has been successfully added to your 
